Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019
Objetivo: determinar el efecto de edad, periodo y cohorte en la mortalidad por tuberculosis en Colombia, durante el periodo1985 a 2019. Materiales y métodos: estudio de cohortes retrospectivas. Se estudiaron todos los fallecimientos por TB ocurridos en Colombia durante 1985 a 2019, tomados del DANE,...
- Autores:
-
Vargas Gómez, Jennifer Patricia
Villanueva Guerrero, Vanessa Rocío
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2025
- Institución:
- Universidad Libre
- Repositorio:
- RIU - Repositorio Institucional UniLibre
- Idioma:
- spa
- OAI Identifier:
- oai:repository.unilibre.edu.co:10901/31547
- Acceso en línea:
- https://hdl.handle.net/10901/31547
- Palabra clave:
- Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019
age
period
cohort
mortality
tuberculosis
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| id |
RULIBRE2_29447fe75b767664c1e70064dcc685a2 |
|---|---|
| oai_identifier_str |
oai:repository.unilibre.edu.co:10901/31547 |
| network_acronym_str |
RULIBRE2 |
| network_name_str |
RIU - Repositorio Institucional UniLibre |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| title |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| spellingShingle |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 age period cohort mortality tuberculosis |
| title_short |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| title_full |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| title_fullStr |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| title_full_unstemmed |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| title_sort |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| dc.creator.fl_str_mv |
Vargas Gómez, Jennifer Patricia Villanueva Guerrero, Vanessa Rocío |
| dc.contributor.advisor.none.fl_str_mv |
Bilbao Ramírez, Jorge Luis Zuluaga de León, Iván de Jesús |
| dc.contributor.author.none.fl_str_mv |
Vargas Gómez, Jennifer Patricia Villanueva Guerrero, Vanessa Rocío |
| dc.subject.spa.fl_str_mv |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 |
| topic |
Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019 age period cohort mortality tuberculosis |
| dc.subject.subjectenglish.spa.fl_str_mv |
age period cohort mortality tuberculosis |
| description |
Objetivo: determinar el efecto de edad, periodo y cohorte en la mortalidad por tuberculosis en Colombia, durante el periodo1985 a 2019. Materiales y métodos: estudio de cohortes retrospectivas. Se estudiaron todos los fallecimientos por TB ocurridos en Colombia durante 1985 a 2019, tomados del DANE, agrupados bajo la causa homologada: “002”. Se calcularon las tasas crudas y estandarizadas por edad (método directo). Para el análisis de edad, periodo y cohorte se utilizó una herramienta web desarrollada por el National Cancer Institute de EE. UU, analizando las derivas locales y las desviaciones lineales, con su prueba de significancia. El efecto de los parámetros de periodo y cohorte se evaluaron mediante el índice de tasas del período y el índice de tasas de la cohorte con IC del 95%. Se utilizó la prueba de Wald, considerando p<0,05 como valor estadísticamente significativo. Resultados: durante 1985 a 2019 hubo 43.092 muertes por TB en Colombia. El departamento con mayor porcentaje de muertes por TB fue Valle del Cauca (15,5%), seguido por Antioquia (11%). Las tasas estandarizadas por edad x 100.00 pasaron de 6,49 en 1985-1989 a 1,92 en 2015-2019. Hubo una tendencia creciente significativa de las tasas de incidencia específicas por edad a lo largo del tiempo en todos los grupos de edad (p<0,05). Las desviaciones de linealidad difirieron significativamente entre los grupos de edad (p<0,05) para todos los periodos y cohortes y la pendiente decreciente en las tasas disminuye de manera más pronunciada en las edades mayores (p<0,05). Conclusión: la mortalidad por TB aumenta progresivamente con la edad, pero ha habido una reducción en la mortalidad a lo largo del tiempo, con un efecto de cohorte significativo, con disminución más pronunciada en las tasas de mortalidad en cohortes más antiguas. |
| publishDate |
2025 |
| dc.date.accessioned.none.fl_str_mv |
2025-07-19T00:51:14Z |
| dc.date.available.none.fl_str_mv |
2025-07-19T00:51:14Z |
| dc.date.created.none.fl_str_mv |
2025-06-21 |
| dc.type.local.spa.fl_str_mv |
Tesis de Especialización |
| dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
| format |
http://purl.org/coar/resource_type/c_7a1f |
| status_str |
acceptedVersion |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10901/31547 |
| url |
https://hdl.handle.net/10901/31547 |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.relation.references.spa.fl_str_mv |
Sharma A, De Rosa M, Singla N, Singh G, Barnwal R, Pandey A. Tuberculosis: an overview of the immunogenic response, disease progression, and medicinal chemistry efforts in the last decade toward the development of potential drugs for extensively drug-resistant tuberculosis strains. J Med Chem. 2021;64(8):4359-95. Bhargava A, Bhargava M. Tuberculosis deaths are predictable and preventable: comprehensive assessment and clinical care is the key. J Clin Tuberc Other Mycobact Dis. 2020;19:100155. Bai W, Ameyaw E. Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021. BMC Public Health. 2024;24(1):12. Vera E, Meroni E. An age-period-cohort approach to the incidence and evolution of overeducation and skills mismatch. Soc Indic Res. 2021;153(2):711-40. Roberto B. Tuberculosis. ¿Es la pandemia ignorada? Rev Mex Patol Clin Med Lab. 2020;1(1):93-112. Natarajan A, Beena P, Devnikar A, Mali S. A systemic review on tuberculosis. Indian J Tuberc. 2020;67(3):295-311. Koch A, Mizrahi V. Mycobacterium tuberculosis. Trends Microbiol. 2018;26(6):555-6. World Health Organization. Global tuberculosis report 2018. Geneva: WHO; 2018. World Health Organization. Global tuberculosis report 2019 [Internet]. Geneva: WHO; 2019 [cited 2023 Dec]. Available from: https://www.who.int/tb/publications/global_report/en/ Romanowski K, Baumann B, Basham C, Khan F, Fox G, Johnston J. Long- term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(2):1129-37. Amaral A, Coton S, Kato B, Tan W, Studnicka M, Janson C, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J. 2015;46:1104-12. Allwood B, Byrne A, Meghji J, Rachow A, van der Zalm M, Schoch O. Post- tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration. 2021;100(8):751-63. Qiu B, Wu Z, Tao B, Li Z, Song H, Tian D, et al. Risk factors for types of recurrent tuberculosis (reactivation versus reinfection): a global systematic review and meta-analysis. Int J Infect Dis. 2022;116:14-20. Obeagu E, Onuoha E. Tuberculosis among HIV patients: a review of prevalence and associated factors. Int J Adv Res Biol Sci. 2023;10(9):128- 34. Ledesma J, Ma J, Vongpradith A, Maddison E, Novotney A, Biehl M, et al. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022;22(2):222-41. Barreto B, Araújo M, Nogueira B, Sobral L, Rodrigues M, Queiroz A, et al. Tuberculosis burden and determinants of treatment outcomes according to age in Brazil: a nationwide study of 896,314 cases reported between 2010 and 2019. Front Med (Lausanne). 2021;8:706689. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2017. Atlanta: CDC; 2018. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FAR, et al. Screening for latent tuberculosis infection in adults: US preventive services task force recommendation statement. JAMA. 2016;316(9):962-9. Instituto Nacional de Salud. Informe de Evento: Tuberculosis Colombia, 2018. Bogotá: INS; 2019. Desikan P, Tiwari K, Panwalkar N, Batra H, Selvaraju S, Jain A. Public health relevance of non-tuberculous mycobacteria among AFB positive sputa. Germs. 2017;7(1):10-8. Rosenberg P, Miranda A. Advances in statistical methods for cancer surveillance research: an age-period-cohort perspective. Front Oncol. 2024;13:1332429. Lan Q, Chen H, Huang Z, Bao T, Liang C, Yi R, et al. Global, regional, and national time trends in incidence for tuberculosis, 1990−2019: an age-period- cohort analysis for the Global Burden of Disease 2019 study. Heart Lung. 2024;65(1):19-30. Law I, Floyd K, African TB Prevalence Survey Group, Abukaraig E, Addo K, Adetifa I, et al. National tuberculosis prevalence surveys in Africa, 2008– 2016: an overview of results and lessons learned. Trop Med Int Health. 2020;25(11):1308-27. World Health Organization. Global tuberculosis report 2020. Geneva: WHO; 2020. Kyu H, Maddison E, Henry N, Mumford J, Barber R, Shields C, et al. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18(3):261-84. Ministerio de Salud, Instituto Nacional de Salud. Comportamiento epidemiológico de la tuberculosis y el SIDA, Colombia 1981-1995. Inf Quinc Epidemiol Nac. 1997;2(6):74-8. Segura A, Rey J, Arbelaéz M. Tendencia de la mortalidad y los egresos hospitalarios por tuberculosis, antes y durante la implementación de la reforma del sector salud, Colombia, 1985-1999. Biomédica. 2004;24:115-23. Allin S, Grignon M. Examining the role of amenable mortality as an indicator of health system effectiveness. Health Policy. 2014;9(3):12-9. Mahapatra P, Shibuya K, Lopez AD, Coullare F, Notzon F, Rao C, et al. Civil registration systems and vital statistics: successes and missed opportunities. Lancet. 2007;370(9599):1653-63. Cendales R, Pardo C. Calidad del certificado de defunción en Colombia. Colomb Med (Cali). 2018;49(1):121-7. Dheda K, Maartens G, Dooley K, McNerney R, Murray M, Furin J, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(17):291-360. Iseman M, Goble M. Multidrug-resistant tuberculosis. N Engl J Med. 1996;334(4):267-8. Uplekar M, Weil D, Lönnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new End TB strategy. Lancet. 2015;385(9979):1799-801. Murray C, Ortblad K, Guinovart C, Lim S, Wolock T, Roberts D, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005-70. World Health Organization. Estrategia Fin a la TB: objetivos e indicadores [Internet]. Geneva: WHO; [cited 2023 Dec]. Available from: https://www.who.int/tb/strategy/end-tb/es/ Barry C, Boshoff H, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7(12):845-55. Esmail H, Barry CE 3rd, Young D, Wilkinson R. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci. 2014;369(1645):20130437. Ministerio de Salud y Protección Social. Resolución Número 227 de 2020, Tuberculosis. Colombia: Ministerio de Salud; 2020. Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, et al. Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis. 2013;19(3):460-3. Reed M, Pichler V, McIntosh F, Mattia A, Fallow A, Masala S, et al. Major Mycobacterium tuberculosis lineages associate with patient country of origin. J Clin Microbiol. 2009;47(4):1119-28. Bos K, Harkins K, Herbig A, Coscolla M, Weber N, Comas I, et al. Pre- Columbian mycobacterial genomes reveal seals as a source of New World human tuberculosis. Nature. 2014;514(7523):494-7. Comas I, Coscolla M, Luo T, Borrell S, Holt K, Kato-Maeda M, et al. Out-of- Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013;45(10):1176-82. Morrison J, Pai M, Hopewell P. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359-68. Cobat A, Gallant C, Simkin L, Black G, Stanley K, Hughes J, et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med. 2009;206(12):2583-91. Rangaka M, Wilkinson K, Glynn J, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45-55. Arend S, van Meijgaarden K, de Boer K, de Palou E, van Soolingen D, Ottenhoff T, et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis. 2002;186(12):1797-807. Pai M, Sotgiu G. Diagnostics for latent tuberculosis infection: incremental, not transformative progress. Eur Respir J. 2016;47(1):704-6. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192-204. Pai M, Denkinger C, Kik S, Rangaka M, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3-20. Pai M, Riley L, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4(12):761-76. Andersen P, Munk M, Pollock J, Doherty T. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099-104. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori G, et al. Interferon- γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):100-11. Pande T, Pai M, Khan F, Denkinger C. Use of chest radiography in the 22 highest tuberculosis burden countries. Eur Respir J. 2015;46(6):1816-9. Esmail H, Lai R, Lesosky M, Wilkinson K, Graham C, Coussens A, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy- 2-[18 F] fluoro-D-glucose positron emission and computed tomography. Nat Med. 2016;22(10):1090-3. Kik S, Denkinger C, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J. 2014;43(6):1793-6. Albert H, Nathavitharana R, Isaacs C, Pai M, Denkinger C, Boehme C. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48(2):516-25. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB [Internet]. Geneva: WHO; 2013 [cited 2023 Dec]. Available from: https://www.who.int/publications/i/item/9789241506335 Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource- constrained settings: informing urgent policy changes. Lancet. 2007;369(9578):2042-9. Peter J, Zijenah L, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016;387(10024):1187-97. Swaminathan S, Ramachandran G. Challenges in childhood tuberculosis. Clin Pharmacol Ther. 2015;98(3):240-4. Caraux P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the elderly. J Clin Med. 2021;10(24):5888. Meintjes G, Brust J, Nuttall J, Maartens G. Management of active tuberculosis in adults with HIV. Lancet HIV. 2019;6(7):e463-74. Akgün K, Crothers K, Pisani M. Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci. 2012;67(3):276-91. Müller L, Di Benedetto S, Pawelec G. The immune system and its dysregulation with aging. Subcell Biochem. 2019;91:21-43. Yew W, Yoshiyama T, Leung C, Chan D. Epidemiological, clinical and mechanistic perspectives of tuberculosis in older people. Respirology. 2018;23(6):567-75. Solana R, Tarazona R, Aiello A, Akbar A, Appay V, Beswick M, et al. CMV and immunosenescence: from basics to clinics. Immun Ageing. 2012;9(1):23. Soma T, Nagata M. Immunosenescence, inflammaging, and lung senescence in asthma in the elderly. Biomolecules. 2022;12(10):1456. Piergallini T, Turner J. Tuberculosis in the elderly: why inflammation matters. Exp Gerontol. 2018;105:32-7. Stýblo K, Meijer J, Sutherland I. The transmission of tubercle bacilli; its trend in a human population. Bull Int Union Tuberc. 1969;41(1):1-104. World Health Organization. TB: a global emergency, WHO report on the TB epidemic. Geneva: WHO; 1994. Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018;6(4):299-314. Cameron N. The growth and development of cohort studies. Ann Hum Biol. 2020;47(2):89-93. Brownlee J. Certain considerations regarding the epidemiology of phthisis pulmonalis. Public Health. 1916;29(1):130-45. Andvord K. Continued studies of tuberculosis considered as a generation illness. Int J Epidemiol. 2008;37(4):917-22. Andvord K. What can we learn by following the development of tuberculosis from one generation to another? Int J Tuberc Lung Dis. 2002;6(7):562-8. Frost W. The age selection of mortality from tuberculosis in successive decades. Am J Epidemiol. 1995;151(1):4-9. Mason W, Smith H. Age-period-cohort analysis and the study of deaths from pulmonary tuberculosis. In: Mason WM, Fienberg SE, editors. Cohort analysis in social research. New York: Springer-Verlag; 1985. p. 151-227. Springett V. An interpretation of statistical trends in tuberculosis. Lancet. 1952;1(6708):575-80. Hertz D, Schneider B. Sex differences in tuberculosis. Semin Immunopathol. 2019;41(2):225-37. Ministerio de Salud y Protección Social. Resolución Número 227 de 2020, Tuberculosis. Colombia: Ministerio de Salud; 2020. Horton K, Hoey A, Béraud G, Corbett E, White R. Systematic review and meta-analysis of sex differences in social contact patterns and implications for tuberculosis transmission and control. Emerg Infect Dis. 2020;26(5):910- 9. Borgdorff M, Nagelkerke N, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis. 2000;4(2):123-32. Horton K, MacPherson P, Houben R, White R, Corbett E. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2016;13(9):e1002119. Hoa N, Sy D, Nhung N, Tiemersma E, Borgdorff M, Cobelens F. National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010;88(4):273-80. Chen C, Zhu T, Wang Z, Peng H, Kong W, Zhou Y. High latent TB infection rate and associated risk factors in the Eastern China of low TB incidence. PLoS One. 2015;10(10):e0141511. Teklu T, Legesse M, Medhin G, Zewude A, Chanyalew M, Zewdie M. Latent tuberculosis infection and associated risk indicators in pastoral communities in southern Ethiopia: a community-based cross-sectional study. BMC Public Health. 2018;18(1):1253. Herzmann C, Sotgiu G, Bellinger O, Diel R, Gerdes S, Goetsch U. Risk for latent and active tuberculosis in Germany. Infection. 2017;45(3):283-91. Ghassemieh B, Attia E, Koelle D, Mancuso J, Narita M, Horne D. Latent tuberculosis infection test agreement in the National Health and Nutrition Examination Survey. Am J Respir Crit Care Med. 2016;194(4):493-500. Smith J, Oeltmann J, Hill A, Tobias J, Boyd R, Click E. Characterizing tuberculosis transmission dynamics in high-burden urban and rural settings. Sci Rep. 2022;12(1):6780. Li M, Lu L, Guo M, Jiang Q, Xia L, Jiang Y. Discrepancy in the transmissibility of multidrug-resistant Mycobacterium tuberculosis in urban and rural areas in China. Emerg Microbes Infect. 2023;12(1):2192301. Ayala A, Ncogo P, Eyene J, García B, Benito A, Romay M. Rural–urban inequities in tuberculosis-related practices in Equatorial Guinea. J Epidemiol Glob Health. 2023;13(4):886-94. Dhamnetiya D, Patel P, Jha R, Shri N, Singh M, Bhattacharyya K. Trends in incidence and mortality of tuberculosis in India over past three decades: a joinpoint and age–period–cohort analysis. BMC Pulm Med. 2021;21(1):152. Ota M, Hirao S, Uchimura K. Age-period-cohort analysis on tuberculosis cases in Japan, 1953–2022. Int J Mycobacteriol. 2023;12(4):486-90. Dong Z, Wang Q, Yu S, Huang F, Liu J, Yao H, et al. Age-period-cohort analysis of pulmonary tuberculosis reported incidence, China, 2006-2020. Infect Dis Poverty. 2022;11(1):62. Segi M. Cancer mortality for selected sites in 24 countries (1950-57). Sendai: Tohoku University of Medicine, Department of Public Health; 1960. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642-56. Viana P, Paiva N, Villela D, Bastos L, De Souza A, Basta P. Factors associated with death in patients with tuberculosis in Brazil: competing risks analysis. PLoS One. 2020;15(10):e0240090. Córdoba C, Buriticá P, Pacheco R, Mancilla A, Valderrama A, Bergonzoli G. Risk factors associated with pulmonary tuberculosis relapses in Cali, Colombia. Biomédica. 2020;40(1):102-12. Martinez L, Cords O, Horsburgh C, Andrews J, Acuna C, Ahuja S, et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973-84. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023. Queiroz A, Berra T, García M, Popolin M, Belchior A, Yamamura M, et al. Spatial pattern and temporal trend of mortality due to tuberculosis. Rev Lat Am Enfermagem. 2018;26:e2992. Lönnroth K, Raviglione M. The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Trans R Soc Trop Med Hyg. 2016;110(3):148-50. Cortez A, Melo A, Neves L, Resende K, Camargos P. Tuberculosis in Brazil: one country, multiple realities. J Bras Pneumol. 2021;47(1):e20200119. Rodrigues I, Aguiar A, Migliori G, Duarte R. Impact of the COVID-19 pandemic on tuberculosis services. Pulmonology. 2022;28(3):210-9. |
| dc.rights.uri.spa.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.license.spa.fl_str_mv |
Atribución-NoComercial-SinDerivadas 2.5 Colombia |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ Atribución-NoComercial-SinDerivadas 2.5 Colombia http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.spa.fl_str_mv |
PDF |
| dc.coverage.spatial.spa.fl_str_mv |
Barranquilla |
| institution |
Universidad Libre |
| bitstream.url.fl_str_mv |
http://repository.unilibre.edu.co/bitstream/10901/31547/4/VARGAS.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/31547/5/VARGAS%20AUTORIZACI%c3%93N.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/31547/3/license.txt http://repository.unilibre.edu.co/bitstream/10901/31547/1/VARGAS.pdf http://repository.unilibre.edu.co/bitstream/10901/31547/2/VARGAS%20AUTORIZACI%c3%93N.pdf |
| bitstream.checksum.fl_str_mv |
41542fa1d1eb9baf570ce23d9c588dd6 fd2c99914d1c72e6a0deb8b20e6f49d0 8a4605be74aa9ea9d79846c1fba20a33 dc58615f02386f3245fc4127c5f37787 afb4c736ed5092d40f970cd826190e8f |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Unilibre |
| repository.mail.fl_str_mv |
repositorio@unilibrebog.edu.co |
| _version_ |
1851053893671190528 |
| spelling |
Bilbao Ramírez, Jorge LuisZuluaga de León, Iván de JesúsVargas Gómez, Jennifer PatriciaVillanueva Guerrero, Vanessa RocíoBarranquilla2025-07-19T00:51:14Z2025-07-19T00:51:14Z2025-06-21https://hdl.handle.net/10901/31547Objetivo: determinar el efecto de edad, periodo y cohorte en la mortalidad por tuberculosis en Colombia, durante el periodo1985 a 2019. Materiales y métodos: estudio de cohortes retrospectivas. Se estudiaron todos los fallecimientos por TB ocurridos en Colombia durante 1985 a 2019, tomados del DANE, agrupados bajo la causa homologada: “002”. Se calcularon las tasas crudas y estandarizadas por edad (método directo). Para el análisis de edad, periodo y cohorte se utilizó una herramienta web desarrollada por el National Cancer Institute de EE. UU, analizando las derivas locales y las desviaciones lineales, con su prueba de significancia. El efecto de los parámetros de periodo y cohorte se evaluaron mediante el índice de tasas del período y el índice de tasas de la cohorte con IC del 95%. Se utilizó la prueba de Wald, considerando p<0,05 como valor estadísticamente significativo. Resultados: durante 1985 a 2019 hubo 43.092 muertes por TB en Colombia. El departamento con mayor porcentaje de muertes por TB fue Valle del Cauca (15,5%), seguido por Antioquia (11%). Las tasas estandarizadas por edad x 100.00 pasaron de 6,49 en 1985-1989 a 1,92 en 2015-2019. Hubo una tendencia creciente significativa de las tasas de incidencia específicas por edad a lo largo del tiempo en todos los grupos de edad (p<0,05). Las desviaciones de linealidad difirieron significativamente entre los grupos de edad (p<0,05) para todos los periodos y cohortes y la pendiente decreciente en las tasas disminuye de manera más pronunciada en las edades mayores (p<0,05). Conclusión: la mortalidad por TB aumenta progresivamente con la edad, pero ha habido una reducción en la mortalidad a lo largo del tiempo, con un efecto de cohorte significativo, con disminución más pronunciada en las tasas de mortalidad en cohortes más antiguas.Universidad Libre, Facultad Ciencias de la Salud, Medicina Interna.Objective: To determine the effect of age, period, and cohort on tuberculosis mortality in Colombia from 1985 to 2019. Materials and methods: A retrospective cohort study. All TB deaths occurring in Colombia from 1985 to 2019 were studied, taken from the DANE (National Institute of Statistics and Census), grouped under the standardized cause: "002." Crude and age-standardized rates were calculated (direct method). A web tool developed by the US National Cancer Institute was used for the age, period, and cohort analysis, analyzing local drifts and linear deviations, with its significance test. The effect of the period and cohort parameters was evaluated using the period rate ratio and the cohort rate ratio with 95% CI. The Wald test was used, considering p <0.05 as statistically significant. Results: From 1985 to 2019, there were 43,092 TB deaths in Colombia. The department with the highest percentage of TB deaths was Valle del Cauca (15.5%), followed by Antioquia (11%). Age-standardized rates x 100.00 increased from 6.49 in 1985-1989 to 1.92 in 2015-2019. There was a significant upward trend in age-specific incidence rates over time in all age groups (p < 0.05). Deviations from linearity differed significantly across age groups (p < 0.05) for all periods and cohorts, and the downward slope in rates decreased more steeply in older ages (p < 0.05). Conclusion: TB mortality increases progressively with age, but there has been a reduction in mortality over time, with a significant cohort effect, with more pronounced declines in mortality rates in older cohorts.PDFspahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Atribución-NoComercial-SinDerivadas 2.5 Colombiainfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Comportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019ageperiodcohortmortalitytuberculosisComportamiento de la mortalidad por tuberculosis según edad, periodo y cohorte, Colombia, 1985 a 2019Tesis de Especializacióninfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisSharma A, De Rosa M, Singla N, Singh G, Barnwal R, Pandey A. Tuberculosis: an overview of the immunogenic response, disease progression, and medicinal chemistry efforts in the last decade toward the development of potential drugs for extensively drug-resistant tuberculosis strains. J Med Chem. 2021;64(8):4359-95.Bhargava A, Bhargava M. Tuberculosis deaths are predictable and preventable: comprehensive assessment and clinical care is the key. J Clin Tuberc Other Mycobact Dis. 2020;19:100155.Bai W, Ameyaw E. Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021. BMC Public Health. 2024;24(1):12.Vera E, Meroni E. An age-period-cohort approach to the incidence and evolution of overeducation and skills mismatch. Soc Indic Res. 2021;153(2):711-40.Roberto B. Tuberculosis. ¿Es la pandemia ignorada? Rev Mex Patol Clin Med Lab. 2020;1(1):93-112.Natarajan A, Beena P, Devnikar A, Mali S. A systemic review on tuberculosis. Indian J Tuberc. 2020;67(3):295-311.Koch A, Mizrahi V. Mycobacterium tuberculosis. Trends Microbiol. 2018;26(6):555-6.World Health Organization. Global tuberculosis report 2018. Geneva: WHO; 2018.World Health Organization. Global tuberculosis report 2019 [Internet]. Geneva: WHO; 2019 [cited 2023 Dec]. Available from: https://www.who.int/tb/publications/global_report/en/Romanowski K, Baumann B, Basham C, Khan F, Fox G, Johnston J. Long- term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(2):1129-37.Amaral A, Coton S, Kato B, Tan W, Studnicka M, Janson C, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J. 2015;46:1104-12.Allwood B, Byrne A, Meghji J, Rachow A, van der Zalm M, Schoch O. Post- tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration. 2021;100(8):751-63.Qiu B, Wu Z, Tao B, Li Z, Song H, Tian D, et al. Risk factors for types of recurrent tuberculosis (reactivation versus reinfection): a global systematic review and meta-analysis. Int J Infect Dis. 2022;116:14-20.Obeagu E, Onuoha E. Tuberculosis among HIV patients: a review of prevalence and associated factors. Int J Adv Res Biol Sci. 2023;10(9):128- 34.Ledesma J, Ma J, Vongpradith A, Maddison E, Novotney A, Biehl M, et al. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022;22(2):222-41.Barreto B, Araújo M, Nogueira B, Sobral L, Rodrigues M, Queiroz A, et al. Tuberculosis burden and determinants of treatment outcomes according to age in Brazil: a nationwide study of 896,314 cases reported between 2010 and 2019. Front Med (Lausanne). 2021;8:706689.Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2017. Atlanta: CDC; 2018.Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FAR, et al. Screening for latent tuberculosis infection in adults: US preventive services task force recommendation statement. JAMA. 2016;316(9):962-9.Instituto Nacional de Salud. Informe de Evento: Tuberculosis Colombia, 2018. Bogotá: INS; 2019.Desikan P, Tiwari K, Panwalkar N, Batra H, Selvaraju S, Jain A. Public health relevance of non-tuberculous mycobacteria among AFB positive sputa. Germs. 2017;7(1):10-8.Rosenberg P, Miranda A. Advances in statistical methods for cancer surveillance research: an age-period-cohort perspective. Front Oncol. 2024;13:1332429.Lan Q, Chen H, Huang Z, Bao T, Liang C, Yi R, et al. Global, regional, and national time trends in incidence for tuberculosis, 1990−2019: an age-period- cohort analysis for the Global Burden of Disease 2019 study. Heart Lung. 2024;65(1):19-30.Law I, Floyd K, African TB Prevalence Survey Group, Abukaraig E, Addo K, Adetifa I, et al. National tuberculosis prevalence surveys in Africa, 2008– 2016: an overview of results and lessons learned. Trop Med Int Health. 2020;25(11):1308-27.World Health Organization. Global tuberculosis report 2020. Geneva: WHO; 2020.Kyu H, Maddison E, Henry N, Mumford J, Barber R, Shields C, et al. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18(3):261-84.Ministerio de Salud, Instituto Nacional de Salud. Comportamiento epidemiológico de la tuberculosis y el SIDA, Colombia 1981-1995. Inf Quinc Epidemiol Nac. 1997;2(6):74-8.Segura A, Rey J, Arbelaéz M. Tendencia de la mortalidad y los egresos hospitalarios por tuberculosis, antes y durante la implementación de la reforma del sector salud, Colombia, 1985-1999. Biomédica. 2004;24:115-23.Allin S, Grignon M. Examining the role of amenable mortality as an indicator of health system effectiveness. Health Policy. 2014;9(3):12-9.Mahapatra P, Shibuya K, Lopez AD, Coullare F, Notzon F, Rao C, et al. Civil registration systems and vital statistics: successes and missed opportunities. Lancet. 2007;370(9599):1653-63.Cendales R, Pardo C. Calidad del certificado de defunción en Colombia. Colomb Med (Cali). 2018;49(1):121-7.Dheda K, Maartens G, Dooley K, McNerney R, Murray M, Furin J, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(17):291-360.Iseman M, Goble M. Multidrug-resistant tuberculosis. N Engl J Med. 1996;334(4):267-8.Uplekar M, Weil D, Lönnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new End TB strategy. Lancet. 2015;385(9979):1799-801.Murray C, Ortblad K, Guinovart C, Lim S, Wolock T, Roberts D, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005-70.World Health Organization. Estrategia Fin a la TB: objetivos e indicadores [Internet]. Geneva: WHO; [cited 2023 Dec]. Available from: https://www.who.int/tb/strategy/end-tb/es/Barry C, Boshoff H, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7(12):845-55.Esmail H, Barry CE 3rd, Young D, Wilkinson R. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci. 2014;369(1645):20130437.Ministerio de Salud y Protección Social. Resolución Número 227 de 2020, Tuberculosis. Colombia: Ministerio de Salud; 2020.Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, et al. Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis. 2013;19(3):460-3.Reed M, Pichler V, McIntosh F, Mattia A, Fallow A, Masala S, et al. Major Mycobacterium tuberculosis lineages associate with patient country of origin. J Clin Microbiol. 2009;47(4):1119-28.Bos K, Harkins K, Herbig A, Coscolla M, Weber N, Comas I, et al. Pre- Columbian mycobacterial genomes reveal seals as a source of New World human tuberculosis. Nature. 2014;514(7523):494-7.Comas I, Coscolla M, Luo T, Borrell S, Holt K, Kato-Maeda M, et al. Out-of- Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013;45(10):1176-82.Morrison J, Pai M, Hopewell P. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359-68.Cobat A, Gallant C, Simkin L, Black G, Stanley K, Hughes J, et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med. 2009;206(12):2583-91.Rangaka M, Wilkinson K, Glynn J, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45-55.Arend S, van Meijgaarden K, de Boer K, de Palou E, van Soolingen D, Ottenhoff T, et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis. 2002;186(12):1797-807.Pai M, Sotgiu G. Diagnostics for latent tuberculosis infection: incremental, not transformative progress. Eur Respir J. 2016;47(1):704-6.Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192-204.Pai M, Denkinger C, Kik S, Rangaka M, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3-20.Pai M, Riley L, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4(12):761-76.Andersen P, Munk M, Pollock J, Doherty T. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099-104.Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori G, et al. Interferon- γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):100-11.Pande T, Pai M, Khan F, Denkinger C. Use of chest radiography in the 22 highest tuberculosis burden countries. Eur Respir J. 2015;46(6):1816-9.Esmail H, Lai R, Lesosky M, Wilkinson K, Graham C, Coussens A, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy- 2-[18 F] fluoro-D-glucose positron emission and computed tomography. Nat Med. 2016;22(10):1090-3.Kik S, Denkinger C, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J. 2014;43(6):1793-6.Albert H, Nathavitharana R, Isaacs C, Pai M, Denkinger C, Boehme C. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48(2):516-25.World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB [Internet]. Geneva: WHO; 2013 [cited 2023 Dec]. Available from: https://www.who.int/publications/i/item/9789241506335Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource- constrained settings: informing urgent policy changes. Lancet. 2007;369(9578):2042-9.Peter J, Zijenah L, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016;387(10024):1187-97.Swaminathan S, Ramachandran G. Challenges in childhood tuberculosis. Clin Pharmacol Ther. 2015;98(3):240-4.Caraux P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the elderly. J Clin Med. 2021;10(24):5888.Meintjes G, Brust J, Nuttall J, Maartens G. Management of active tuberculosis in adults with HIV. Lancet HIV. 2019;6(7):e463-74.Akgün K, Crothers K, Pisani M. Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci. 2012;67(3):276-91.Müller L, Di Benedetto S, Pawelec G. The immune system and its dysregulation with aging. Subcell Biochem. 2019;91:21-43.Yew W, Yoshiyama T, Leung C, Chan D. Epidemiological, clinical and mechanistic perspectives of tuberculosis in older people. Respirology. 2018;23(6):567-75.Solana R, Tarazona R, Aiello A, Akbar A, Appay V, Beswick M, et al. CMV and immunosenescence: from basics to clinics. Immun Ageing. 2012;9(1):23.Soma T, Nagata M. Immunosenescence, inflammaging, and lung senescence in asthma in the elderly. Biomolecules. 2022;12(10):1456.Piergallini T, Turner J. Tuberculosis in the elderly: why inflammation matters. Exp Gerontol. 2018;105:32-7.Stýblo K, Meijer J, Sutherland I. The transmission of tubercle bacilli; its trend in a human population. Bull Int Union Tuberc. 1969;41(1):1-104.World Health Organization. TB: a global emergency, WHO report on the TB epidemic. Geneva: WHO; 1994.Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018;6(4):299-314.Cameron N. The growth and development of cohort studies. Ann Hum Biol. 2020;47(2):89-93.Brownlee J. Certain considerations regarding the epidemiology of phthisis pulmonalis. Public Health. 1916;29(1):130-45.Andvord K. Continued studies of tuberculosis considered as a generation illness. Int J Epidemiol. 2008;37(4):917-22.Andvord K. What can we learn by following the development of tuberculosis from one generation to another? Int J Tuberc Lung Dis. 2002;6(7):562-8.Frost W. The age selection of mortality from tuberculosis in successive decades. Am J Epidemiol. 1995;151(1):4-9.Mason W, Smith H. Age-period-cohort analysis and the study of deaths from pulmonary tuberculosis. In: Mason WM, Fienberg SE, editors. Cohort analysis in social research. New York: Springer-Verlag; 1985. p. 151-227.Springett V. An interpretation of statistical trends in tuberculosis. Lancet. 1952;1(6708):575-80.Hertz D, Schneider B. Sex differences in tuberculosis. Semin Immunopathol. 2019;41(2):225-37.Ministerio de Salud y Protección Social. Resolución Número 227 de 2020, Tuberculosis. Colombia: Ministerio de Salud; 2020.Horton K, Hoey A, Béraud G, Corbett E, White R. Systematic review and meta-analysis of sex differences in social contact patterns and implications for tuberculosis transmission and control. Emerg Infect Dis. 2020;26(5):910- 9.Borgdorff M, Nagelkerke N, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis. 2000;4(2):123-32.Horton K, MacPherson P, Houben R, White R, Corbett E. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2016;13(9):e1002119.Hoa N, Sy D, Nhung N, Tiemersma E, Borgdorff M, Cobelens F. National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010;88(4):273-80.Chen C, Zhu T, Wang Z, Peng H, Kong W, Zhou Y. High latent TB infection rate and associated risk factors in the Eastern China of low TB incidence. PLoS One. 2015;10(10):e0141511.Teklu T, Legesse M, Medhin G, Zewude A, Chanyalew M, Zewdie M. Latent tuberculosis infection and associated risk indicators in pastoral communities in southern Ethiopia: a community-based cross-sectional study. BMC Public Health. 2018;18(1):1253.Herzmann C, Sotgiu G, Bellinger O, Diel R, Gerdes S, Goetsch U. Risk for latent and active tuberculosis in Germany. Infection. 2017;45(3):283-91.Ghassemieh B, Attia E, Koelle D, Mancuso J, Narita M, Horne D. Latent tuberculosis infection test agreement in the National Health and Nutrition Examination Survey. Am J Respir Crit Care Med. 2016;194(4):493-500.Smith J, Oeltmann J, Hill A, Tobias J, Boyd R, Click E. Characterizing tuberculosis transmission dynamics in high-burden urban and rural settings. Sci Rep. 2022;12(1):6780.Li M, Lu L, Guo M, Jiang Q, Xia L, Jiang Y. Discrepancy in the transmissibility of multidrug-resistant Mycobacterium tuberculosis in urban and rural areas in China. Emerg Microbes Infect. 2023;12(1):2192301.Ayala A, Ncogo P, Eyene J, García B, Benito A, Romay M. Rural–urban inequities in tuberculosis-related practices in Equatorial Guinea. J Epidemiol Glob Health. 2023;13(4):886-94.Dhamnetiya D, Patel P, Jha R, Shri N, Singh M, Bhattacharyya K. Trends in incidence and mortality of tuberculosis in India over past three decades: a joinpoint and age–period–cohort analysis. BMC Pulm Med. 2021;21(1):152.Ota M, Hirao S, Uchimura K. Age-period-cohort analysis on tuberculosis cases in Japan, 1953–2022. Int J Mycobacteriol. 2023;12(4):486-90.Dong Z, Wang Q, Yu S, Huang F, Liu J, Yao H, et al. Age-period-cohort analysis of pulmonary tuberculosis reported incidence, China, 2006-2020. Infect Dis Poverty. 2022;11(1):62.Segi M. Cancer mortality for selected sites in 24 countries (1950-57). Sendai: Tohoku University of Medicine, Department of Public Health; 1960.Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642-56.Viana P, Paiva N, Villela D, Bastos L, De Souza A, Basta P. Factors associated with death in patients with tuberculosis in Brazil: competing risks analysis. PLoS One. 2020;15(10):e0240090.Córdoba C, Buriticá P, Pacheco R, Mancilla A, Valderrama A, Bergonzoli G. Risk factors associated with pulmonary tuberculosis relapses in Cali, Colombia. Biomédica. 2020;40(1):102-12.Martinez L, Cords O, Horsburgh C, Andrews J, Acuna C, Ahuja S, et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973-84.World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.Queiroz A, Berra T, García M, Popolin M, Belchior A, Yamamura M, et al. Spatial pattern and temporal trend of mortality due to tuberculosis. Rev Lat Am Enfermagem. 2018;26:e2992.Lönnroth K, Raviglione M. The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Trans R Soc Trop Med Hyg. 2016;110(3):148-50.Cortez A, Melo A, Neves L, Resende K, Camargos P. Tuberculosis in Brazil: one country, multiple realities. J Bras Pneumol. 2021;47(1):e20200119.Rodrigues I, Aguiar A, Migliori G, Duarte R. Impact of the COVID-19 pandemic on tuberculosis services. Pulmonology. 2022;28(3):210-9.THUMBNAILVARGAS.pdf.jpgVARGAS.pdf.jpgIM Thumbnailimage/jpeg10418http://repository.unilibre.edu.co/bitstream/10901/31547/4/VARGAS.pdf.jpg41542fa1d1eb9baf570ce23d9c588dd6MD54VARGAS AUTORIZACIÓN.pdf.jpgVARGAS AUTORIZACIÓN.pdf.jpgIM Thumbnailimage/jpeg28669http://repository.unilibre.edu.co/bitstream/10901/31547/5/VARGAS%20AUTORIZACI%c3%93N.pdf.jpgfd2c99914d1c72e6a0deb8b20e6f49d0MD55LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/31547/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALVARGAS.pdfVARGAS.pdfapplication/pdf3284881http://repository.unilibre.edu.co/bitstream/10901/31547/1/VARGAS.pdfdc58615f02386f3245fc4127c5f37787MD51VARGAS AUTORIZACIÓN.pdfVARGAS AUTORIZACIÓN.pdfapplication/pdf15551206http://repository.unilibre.edu.co/bitstream/10901/31547/2/VARGAS%20AUTORIZACI%c3%93N.pdfafb4c736ed5092d40f970cd826190e8fMD5210901/31547oai:repository.unilibre.edu.co:10901/315472025-11-06 12:28:04.424Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.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 |